Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.641487
Title: Modifying factors in the phenotypic expression of hypertrophic cardiomyopathy
Author: Begley, D. A.
Awarding Body: University of Edinburgh
Current Institution: University of Edinburgh
Date of Award: 2008
Availability of Full Text:
Full text unavailable from EThOS.
Please contact the current institution’s library for further details.
Abstract:
The objectives of this study were to assess the role of potential modifying factors in the phenotypic expression of hypertrophic cardiomyopathy (HCM) and to assess therapeutic options that might cause regression of left ventricular (LV) mass in HCM. A total of 269 patients were included to assess the role of gender, insulin-like growth factor-I (IGF-I) and genetic polymorphisms in the angiotensin converting enzyme (ACE) and endothelin-1 (ET-1) genes in determining LV mass in HCM. The relationship between brain natriuretic peptide (BNP) and HCM caused by known sarcomeric mutations was also assessed. The role of ACE inhibition and/or blockade was also assessed in regression of LV hypertrophy in non-obstructive HCM. Female patients were found to have relatively thicker hearts with smaller cavities than male patients as in LV hypertrophy caused by pressure overload. Higher physiological levels of IGF-I were associated with lesser degrees of LVH which may be due to increased muscular efficiency. BNP levels were associated with the disease causing mutation but not to the degree of LVH. Mutations associated with an adverse prognosis had significantly higher BNP levels. The insertion/deletion (I/D) ACE gene but not ET-1 gene polymorphism was associated with LV mass in HCM. Treatment with enalparil alone or in combination with losartan resulted in a 7% and 8.55 reduction in LV mass respectively over 6 months. These studies suggest that identifying modifying factors is important to explore therapeutic options in the management of these patients. In addition further studies exploring the long term impact of such therapies on disease progression are indicated and their role in disease prevention in pre-clinical states.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.641487  DOI: Not available
Share: